Insider Selling: uniQure N.V. (NASDAQ:QURE) Director Sells 2,112 Shares of Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Madhavan Balachandran sold 2,112 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the transaction, the director now directly owns 37,697 shares of the company's stock, valued at $544,721.65. The trade was a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

uniQure Price Performance

Shares of NASDAQ QURE traded up $0.27 during trading on Tuesday, reaching $14.22. The company had a trading volume of 852,314 shares, compared to its average volume of 1,953,833. uniQure N.V. has a 52 week low of $3.73 and a 52 week high of $19.18. The business's 50 day moving average price is $14.29 and its 200-day moving average price is $13.99. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. The stock has a market cap of $778.97 million, a PE ratio of -3.24 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The company had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. Analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on QURE shares. Guggenheim restated a "buy" rating and issued a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Chardan Capital restated a "buy" rating and issued a $38.00 price target on shares of uniQure in a research report on Friday, May 30th. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Finally, Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $37.82.

Institutional Investors Weigh In On uniQure

Institutional investors have recently modified their holdings of the business. Twin Tree Management LP acquired a new stake in shares of uniQure during the 4th quarter worth approximately $77,000. ADAR1 Capital Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth approximately $177,000. Mraz Amerine & Associates Inc. acquired a new stake in shares of uniQure during the 1st quarter worth approximately $106,000. Wells Fargo & Company MN grew its position in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after buying an additional 1,503 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of uniQure during the 1st quarter worth approximately $152,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.